Venture Investors Health
SlowingMadison, WIBiotechnology, Healthcare, PharmaceuticalsLast fund filed October 2023
6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Venture Investors Health Fund 7 | October 2023 | $100M | $57M | 18 |
| Venture Investors Health Fund 6 | May 2018 | $100M | $73M | 27 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| James Adox | Slowing | Medical devices, Enterprise software, Biotech & pharma | 9 | 1 |
| David Arnstein | Quiet | None listed | 0 | 0 |
| John Neis | Quiet | Biotech & pharma, Digital health, Medical devices | 6 | 0 |
| Joseph Amaral | Quiet | Medical devices | 1 | 0 |
| Paul Weiss | Quiet | Biotech & pharma | 9 | 0 |
| Scott Button | Quiet | Medical devices, Digital health, Climate & energy | 6 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Venture Investors Health’s own portfolio companies, based on 30 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Venture Investors Health’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Arboretum Ventures | 3 | Delphinus Medical Technologies, Health Scholars, ViaLase |
| BioStar Ventures | 2 | Delphinus Medical Technologies, Great Lakes Pharmaceuticals |
| U.S Venture Partners | 2 | Reshape Medical, ViaLase |
| Versant Venture Capital | 2 | NEUWAVE MEDICAL, ViaLase |
| ARCH Venture Partners | 1 | Cellectar Biosciences |
| HealthX Ventures | 1 | ENSODATA |
| Jump Capital | 1 | Health Scholars |
| New Leaf | 1 | Reshape Medical |
| Pandemic Innovation | 1 | ENSODATA |
| SV Life Sciences | 1 | Reshape Medical |
| Vensana Capital | 1 | NEUWAVE MEDICAL |
| Zetta Venture Partners | 1 | ENSODATA |
A shared board seat: a company where filings name a Venture Investors Health partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.